<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545961</url>
  </required_header>
  <id_info>
    <org_study_id>Diary nr 41/2007</org_study_id>
    <nct_id>NCT00545961</nct_id>
  </id_info>
  <brief_title>Middle Meatal Bacteriology During Acute Respiratory Infection in Children</brief_title>
  <official_title>Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oulu University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether the children with respiratory infection and
      the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the
      nasal middle meatus benefit from antimicrobial treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute sinusitis is one of the most common disease in children requiring antimicrobial
      treatment. The diagnosis and treatment outcomes of acute sinusitis are contradictory, and
      better diagnostic criteria are needed. In adults with acute maxillary sinusitis, bacterial
      culture results obtained from the nasal middle meatus are comparable to those obtained from
      sinus puncture and aspiration. In children, the presence of pathogenic bacteria (S.
      pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory
      infection predicts longer duration of signs and symptoms of common cold.

      In this randomized placebo-controlled study, the effect of the antimicrobial treatment
      (amoxicillin-clavulanate) is examined in children with pathogenic bacteria (S. pneumoniae, H.
      influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection. The
      duration of the symptoms and speed of recovery is recognized by daily symptom-diary, the
      results are compared between the treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry.</measure>
    <time_frame>within the first 3 weeks after enrolment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration (days)and severity (grade mild, severe) of different symptoms (clear nasal discharge, coloured nasal discharge, nasal obstruction, cough, throat pain, ear ache, fever, headache, diarrhea)</measure>
    <time_frame>within the first three weeks after enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days the child is using the following symptomatic drugs (pain killers, nasal vasoconstrictors, nasal corticosteroids, asthma drugs, antihistamines)</measure>
    <time_frame>within the first three weeks after the enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days the child is not at school and that the parents are not at work</measure>
    <time_frame>within the first three weeks after enrolment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Respiratory Infection</condition>
  <condition>Sinusitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amoxicillin-clavulanate acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>mixture, 0.28125 ml/kg twice a day for 7 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ora-Plus (registered trademark) mixture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin clavulanate acid</intervention_name>
    <description>mixture 0.28125 ml / kg twice a day for 7 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Clavurion mixture (Orion Oy)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute respiratory infection with nasal symptoms (nasal obstruction or discharge)

          -  seeking medical help from health centre for the respiratory symptoms

          -  pathogenic bacteria (S pneumoniae, H influenzae or M catarrhalis) identified from
             right or left nasal middle meatus in the endoscopically taken swab culture sampling
             taken by a study investigator (all microbiological analyses are done by the National
             Public Health Institute´s microbiological laboratory in Oulu)

        Exclusion Criteria:

          -  otitis, tonsillitis or other disease requiring antimicrobial treatment

          -  respiratory infection within 4 weeks of screening

          -  antimicrobial treatment within 4 weeks of screening

          -  allergy to penicillin or amoxicillin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jukka-Pekka Kuusiniemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Otolaryngology, Seinäjoki Central Hospital, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eeva Löfgren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Otolaryngology, Kokkola Central Hospital, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Marttila, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Otolaryngology, University of Oulu, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olli-Pekka Alho, professor</last_name>
    <role>Study Director</role>
    <affiliation>Dept of Otolaryngology, University of Oulu, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aila Kristo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept of Otolaryngology, University of Oulu, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulla Lantto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Otolaryngology, University of Oulu, Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aila A Kristo, MD</last_name>
    <phone>+35883153492</phone>
    <email>aila.kristo@ppshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olli-Pekka Alho, MD</last_name>
    <phone>+35883153473</phone>
    <email>olli-pekka.alho@oulu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Keski-pohjanmaan keskussairaala</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eeva Löfgren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aila Kristo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Marttila, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulla Lantto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Etelä-Pohjanmaan Keskussairaala</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jukka-Pekka Kuusiniemi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2007</study_first_submitted>
  <study_first_submitted_qc>October 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2007</study_first_posted>
  <last_update_submitted>October 18, 2007</last_update_submitted>
  <last_update_submitted_qc>October 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2007</last_update_posted>
  <keyword>respiratory infection</keyword>
  <keyword>sinusitis</keyword>
  <keyword>rhinosinusitis</keyword>
  <keyword>children</keyword>
  <keyword>middle meatal specimens</keyword>
  <keyword>respiratory track bacteria</keyword>
  <keyword>amoxicillin-clavulanate</keyword>
  <keyword>pneumococci</keyword>
  <keyword>haemophilus</keyword>
  <keyword>moraxella</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

